Nitrous oxide (N 2 O) has been used for well over 150 years in clinical dentistry for its analgesic and anxiolytic properties. This small and simple inorganic chemical molecule has indisputable effects of analgesia, anxiolysis, and anesthesia that are of great clinical interest. Recent studies have helped to clarify the analgesic mechanisms of N 2 O, but the mechanisms involved in its anxiolytic and anesthetic actions remain less clear. Findings to date indicate that the analgesic effect of N 2 O is opioid in nature, and, like morphine, may involve a myriad of neuromodulators in the spinal cord. The anxiolytic effect of N 2 O, on the other hand, resembles that of benzodiazepines and may be initiated at selected subunits of the ␥-aminobutyric acid type A (GABA A ) receptor. Similarly, the anesthetic effect of N 2 O may involve actions at GABA A receptors and possibly at N-methyl-D-aspartate receptors as well. This article reviews the latest information on the proposed modes of action for these clinical effects of N 2 O.
N
itrous oxide (N 2 O) was discovered in 1793 by the English scientist Joseph Priestley, who also discovered oxygen (O 2 ). In 1799, Sir Humphrey Davy administered N 2 O to visitors at the Pneumatic Institute and gave it for the first time the term ''laughing gas.'' He astutely noted the analgesic effects of the gas and even predicted its application in suppression of pain during surgical procedures. However, for the next 40 years or so, the primary use of N 2 O was for recreational enjoyment and public shows. N 2 O found a more scientific use as an anesthetic in clinical dentistry and medicine in the early 1840s. Horace Wells, an American dentist, had one of his own teeth extracted while inhaling N 2 O-the first demonstration of clinical anesthesia. There followed a period of wide clinical use of N 2 O for dental anesthesia, which, unfortunately, was followed by a period of abandonment when it was recognized that the high concentrations required for anesthesia frequently placed the patient at risk of severe hypoxia and death from as-phyxiation. Although the specific manner of use of N 2 O has changed considerably in the past 150 years, it remains today the most widely used of all general anesthetic agents and plays an all-important role in both dental and medical practice. The introduction of anesthesia through N 2 O is considered a great achievement in dentistry, comparable to the discovery of local anesthesia and the fluoridation of water. 1, 2 Today the common medical uses of N 2 O include balanced anesthesia during surgery, wherein N 2 O is frequently combined with other general anesthetic drugs and nonanesthetic preoperative drugs, and analgesia for the relief of pain in clinical as well as emergency situations. There are significant nonmedical uses of N 2 O as well. In industry, N 2 O is used as an oxidizer in atomic absorption spectrometry and in the manufacture of semiconductors. In the dairy industry, N 2 O is used as a bacteriostatic, tasteless, odorless food processing propellant. N 2 O is also injected into the air intake of car engines by racing enthusiasts to boost horsepower. N 2 O is also used to prepare divers for deep dives because it mimics the disorientation and behavioral changes of decompression illness (the ''bends'') when a diver surfaces from the depths too rapidly.
For nearly 150 years since its discovery, N 2 O has been used by clinicians without a clear knowledge of its mechanisms of action. Only over the last 20-30 years has there been any significant research elucidating the mechanisms of the analgesic, antianxiety, and anesthetic effects of N 2 O. In 1985, Eger published the first comprehensive book on N 2 O, gathering all available information up to that time and providing an excellent summary of clinical and research issues. 3 Since then, a large amount of research has been added, clarifying a number of issues about the actions of This timely review will update readers on the current state of knowledge of the pharmacokinetic and pharmacodynamic aspects of N 2 O. The relevant clinical uses of N 2 O as an analgesic, anxiolytic, and anesthetic drug will be explored.
ANALGESIA
Subanesthetic concentrations of N 2 O produce only analgesic and anxiolytic effects without unconsciousness. 4 Analgesic N 2 O has a long history of use in obstetrics for relief of labor pain.
5 N 2 O is also used for self-administered analgesia in cancer patients, 6 preemptive analgesia, 7 and to alleviate pain and discomfort associated with a number of medical procedures, including intra-articular drug injection, 8 peripheral intravenous cannulation, 9 sigmoidoscopy, 10 colonoscopy, 11 ophthalmologic procedures, 12 and biopsy procedures. 13 In Europe, Entonox (BOC Group), a 50% N 2 O : 50% oxygen mixture, is widely used in emergency medical care of patients in accident scenes and during ambulance transportation.
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The mechanism of the analgesic effect of N 2 O is gradually being clarified through elucidation of the antinociceptive effect of N 2 O in animals. Because animals are unable to report a reduction in sensation of pain, analgesia is more properly determined in animals as antinociception or a diminished responsiveness to a noxious stimulus.
The Opioid Hypothesis of N 2 O Antinociceptive Action
It was as early as 1943 when the analgesic effect of N 2 O was judged to be comparable to that of opioid analgesic drugs-30% of N 2 O was deemed to be equieffective as 10-15 mg of morphine. 17 It was not until the mid1970s that it was first reported that N 2 O-induced antinociception in mice and rats was sensitive to blockade by the narcotic antagonist naloxone. 18 ,19 N 2 O-induced analgesia in human subjects was also antagonized by naloxone. [20] [21] [22] [23] A large number of studies have established an important role for opioid receptors in the periaqueductal gray (PAG) area of the midbrain in pain modulation. 24 The N 2 O-induced analgesic effect could be completely ablated after lesioning the PAG in the rat 25 or following microinjection of opioid antagonists into the PAG. [26] [27] [28] Although these results clearly implicate opioid receptors in mediation of N 2 O-induced antinociception and analgesia, it is appreciated today that opioid receptors are not a monolithic species. There are multiple opioid receptors that are capable of mediating pain relief, and the specific subtypes of opioid receptors that mediate the antinociceptive effects of N 2 O appear to depend on various factors including the species and/or strain, the regions of the brain, and the experimental noxious stimulus. 29 In the mouse abdominal constriction test, N 2 O antinociception was unaffected by either or ␦ opioid antagonists but was sensitive to blockade by drugs with antagonist properties at opioid receptors.
30,31 A opioid ligand also protected N 2 O antinociception in mice from antagonism by an irreversible, nonselective opioid antagonist. 32 The opioid receptor subtype appears to be involved at both the supraspinal and spinal cord levels in suppression of chemical noxious stimulation, 33 which is supported by observations that N 2 O-induced antinociception was antagonized by supraspinal and spinal pretreatment with antisera against the endogenous opioid ligand, dynorphin (DYN). 34, 35 In the rat hot plate test, and opioid receptor subtypes appear to perform a main function at the supraspinal level, as demonstrated by the effectiveness of and ⑀ opioid antagonists to reduce N 2 O-induced antinociception. 26 The opioid connection was further strengthened by reports of morphine-tolerant animals being cross-tolerant to N 2 O.
19,36 The fact that cross-tolerance was unilateral in that N 2 O-tolerant animals were not cross-tolerant to morphine led Berkowitz et al to hypothesize that N 2 O might work through stimulating the neuronal release of endogenous opioid peptides.
36 Chronic treatment with morphine results in desensitization of opioid receptors and/or signal transduction mechanisms, hence resulting in cross-tolerance to N 2 O, which relies on the same opioid receptors. Chronic treatment with N 2 O results in a tolerance that is attributable to excessive depletion of endogenous opioid peptide stores, such that a subsequent exposure to N 2 O is unable to release sufficient quantities of opioid peptides to cause antinociception. The chronic exposures to N 2 O in these tolerance investigations were not sufficient for inducing the same changes at the receptor and/or signal levels that were observed in the chronic morphine studies.
The first chemical evidence for N 2 O-induced release of opioid peptides did not emerge until nearly 10 years following the first report of naloxone antagonism of N 2 O-induced antinociception. Exposure to 75% N 2 O for 60 minutes increased by 2-fold the amount of immunoreactive methionine-enkephalin (ME) in fractions of perfusate collected from ventricular-cisternally perfused rats. 37 At the end of N 2 O exposure, the levels of immunoreactive ME returned to baseline. This led to the conclusion that N 2 O was capable of inducing the neuronal release of either ME itself or a ME-like peptide in the rat brain. Later studies also showed that N 2 O increased ␤-endorphin concentrations in the arcuate propriomelanocortin neuronal system in rats, 38 a result that was reproduced in an in vitro system.
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The most extensive studies have been conducted in the mouse abdominal constriction test. The opioid peptide released by N 2 O was identified as DYN in experiments utilizing rabbit antisera against rat opioid peptides. N 2 O antinociception was antagonized by intracerebroventricular pretreatment with antisera against DYN 1-8 and DYN [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] but not ME or ␤-endorphin. 34 In a subsequent study, it was discovered that N 2 O antinociception was also sensitive to antagonism by intrathecal pretreatment with antisera to DYN 1-8 , DYN [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] , and ME. 35 These findings are consistent with studies reporting that activation of supraspinal opioid receptors causes a release of ME in the spinal cord. 40 Therefore, in this one experimental model, it appears that N 2 O evokes its antinociceptive effect through the supraspinal release of various DYNs, which are the endogenous ligands of opioid receptors, and spinal release of DYNs and ME.
Involvement of Nitric Oxide in N 2 O Antinociception
Nitric oxide (NO) is a naturally occurring gas that only recently has been recognized as an endogenous biological regulator of great significance. Science magazine declared NO as ''The Molecule of the Year'' for 1992. 41 There is evidence that NO released from nitrergic neurons seems to regulate the release of a variety of transmitters (acetylcholine, catecholamines, excitatory and inhibitory amino acids, serotonin, histamine, and adenosine) in the brain. 42 . 43 Later studies demonstrated that N 2 O-induced antinociception was more specifically antagonized by pretreatment with a selective inhibitor of neuronal NOS 44 or an antisense oligodeoxynucleotide directed against neuronal NOS.
45 Nitric oxide also appears to play a key role in opioid peptide release. A tangential study was designed to test this hypothesis. If N 2 O antinociception in the abdominal constriction model is caused by stimulated release of DYNs, which then activate opioid receptors, and if NO appears not to influence opioid receptor or signal transduction, then it is possible that NO influences the stimulated release of DYNs. 46 (See Figure 1 ) Further evidence of the importance of NO in N 2 O antinociception emerged from experiments in inbred mouse strains. N 2 O evoked a concentration-dependent antinociception in various mouse strains, including the C57BL/6 inbred strain, but DBA/2 inbred mice exposed to identical levels of N 2 O responded with only a weak antinociceptive effect. 47, 48 When mice were exposed to N 2 O, there was increased whole-brain NOS activity-as quantified by radioconversion of [
14 C]L-arginine to [
14 C]L-citrulline-in the C57BL/6 mouse but not the DBA/2 mouse. 49 This apparent correlation between antinociceptive responsiveness and increase in NOS enzyme activity was recently confirmed in mice selectively bred for low sensitivity to N 2 O-induced antinociception. 50 Quantitative trait loci analysis in C57BL/6 and DBA/ 2 mice, their B6D2F 1 offspring, 22 BXD recombinant inbred strains (derived from the progenitors), and 600 offspring bred from the F 2 generation identified 2 markers from chromosomes 2 and 5 that were significantly correlated with N 2 O antinociception and 1 marker from chromosome 18 that was suggestive. 48, 51 It is significant that the genetic control of neuronal NOS is localized to mouse chromosome 5 in the same vicinity as one of the significant markers in the quantitative trait loci analysis. 52 Determination of other NOS-related factors may also be located in the same area of the chromosome.
Therefore, it seems likely that in the mouse abdominal constriction model, NO provokes the release of endogenous opiates (DYN peptides) playing a mediatory role in the antinociceptive effect of N 2 O. The location of the nerve terminals from which DYN is released and the location of the opioid receptors have not been determined.
Descending Pathways Activated by N 2 O
Fujinaga and Maze 53 hypothesized that the release of endogenous opioid peptides and the subsequent stimulation of opioid receptors activate descending pathways that modulate nociceptive processing in the spinal cord. There are several steps to this process, as demonstrated by a series of elegant studies conducted in rats. A nor- adrenergic pathway is the most important descending pathway; however, it is under tonic inhibition by a ␥-aminobutyric acid (GABA)-ergic pathway in the A7 area of the pons. The stimulation of opioid receptors by N 2 O-released opioid peptides inhibits the inhibitory GABA-ergic pathway, thus causing disinhibition of the descending noradrenergic pathway.
This hypothesis is borne out by the experimental evidence. Transection of the spinal cord prevents the antinociceptive response to N 2 O. 54 Microinjection of opioid receptor antagonists into the PAG effectively blocks the antinociceptive effect of N 2 O, [26] [27] [28] whereas opioid antagonists administered intrathecally have no effect. 55 Conversely, intrathecal but not supraspinal administration of ␣ 2 adrenergic receptor blockers antagonizes N 2 O-induced antinociception. 55 Studies in transgenic mice indicate that ␣ 2B and/or ␣ 2C but not ␣ 2A adrenergic receptors are responsible for the antinociceptive effect of N 2 O.
56 Alpha 1 adrenergic receptors have also been implicated in N 2 O-induced antinociception. 57 Depletion of norepinephrine in the spinal cord antagonizes the antinociceptive effect of N 2 O. 54 Descending noradrenergic inhibitory neurons are not functional at birth and take at least 3 weeks to fully develop in rats. 58 It has been suggested that the central nervous system of a 3-week-old rat is equivalent to that of a human at the toddler stage. 59 This may explain experimental observations that rats do not exhibit sensitivity to the antinociceptive effects of N 2 O before 4 weeks of age. 60, 61 Although the sequential neurological developments in rat and human central nervous systems are not totally comparable, these results suggest that N 2 O may not be efficacious as an analgesic agent in early childhood.
The disinhibited noradrenergic pathway appears to modulate spinal nociceptive processing by 2 divergent pathways ( Figure 2 ). One population of ␣ 2 adrenergic receptors is located on second-order neurons in the pain pathway, whereas the other is located on inhibitory GABA interneurons in the spinal cord. This dual involvement of GABA as pronociceptive supraspinally and antinociceptive spinally is consistent with experimental findings. N 2 O-induced antinociception was antagonized by intracerebroventricular administration of muscimol, a GABA type A (GABA A ) agonist, and intrathecal administration of gabazine, a GABA A antagonist. 62 Immunohistochemical and in situ hybridization identification of the immediate early gene c-fos or the FOS protein that it encodes can be used to map functional activation in discrete brain regions of rats following physiological, pharmacological, or psychological stimulation. N 2 O exposure increases c-Fos expression in the pontine noradrenergic nuclei as well as the spinal cord.
63 N 2 O-induced c-Fos expression in the spinal cord was colocalized to cells containing the rate-limiting enzyme in the synthesis of GABA. 64 Expression of c-Fos in these regions was antagonized by opioid receptor blockade and also by stimulation of GABA A receptors in the PAG. Microinjection of opioid antagonist and GA-BA A agonist into the pontine A7 nuclei also inhibited N 2 O-induced expression of c-Fos in the spinal cord as well as attenuate N 2 O-induced antinociception. 
Tolerance to N 2 O Antinociception
As with many centrally mediated drug effects, continuous administration of N 2 O results in development of tolerance to the antinociceptive effect of N 2 O in experimental animals 39 and to the analgesic effect of N 2 O in human subjects. 65 Studies in different rat strains have provided valuable insight into the development of tolerance to N 2 O. The Fischer rat strain exhibits a robust antinociceptive response to N 2 O but does not show acute tolerance, whereas the Lewis rat strain is poorly responsive to N 2 O-induced antinociception. 66 In addi- tion to differential sensitivity to N 2 O, the Fisher and Lewis rats also differ in neurochemistry and behavioral reactions to other centrally active drugs. 67, 68 Compared to the Fischer rat, the poorly responsive Lewis strain has lower basal levels of endogenous opioid peptides and does not respond with an increase in opioid peptide levels following the administration of morphine.
68 This is also consistent with findings that maintenance of high levels of opioid peptide by inhibiting enkephalinase enzyme can prevent the development of acute tolerance to N 2 O in rats.
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ANXIOLYSIS
In dentistry, subanesthetic concentrations of N 2 O are routinely used to produce moderate sedation for dental surgery in anxious patients. 70 Minimal and moderate sedation (or conscious sedation, as was the previous terminology used) is mediated by the administration of agents causing alterations in the level of consciousness, cognition, motor coordination, degree of anxiety, and physiological parameters. It is not defined by specific medications or their doses but instead by the patient's response: the patient must retain the ability to respond purposefully to verbal commands either alone or accompanied by light tactile stimulation. 71 In pediatric dentistry, N 2 O is an invaluable tool in managing the mildly to moderately anxious child. The ease of its administration, its wide margin of safety, its analgesic and anxiolytic effects, and, most of all, its rapid reversibility make it an ideal drug for use in children. [72] [73] [74] [75] The most recent survey of the active members of the American Academy of Pediatric Dentistry by Houpt 76 reported that 61% of 1758 respondents used N 2 O/O 2 with other sedative agents. The American Academy of Pediatric Dentistry recognizes nitrous oxide/oxygen inhalation as a safe and effective technique to reduce anxiety, produce analgesia, and enhance effective communication between a patient and health care provider. 71 There is evidence that the relaxation and relief from anxiety during inhalation of N 2 O is a specific anxiolytic effect that is independent of the analgesic action of 86, 87 In the light/dark exploration test, selective neuronal NOS inhibitors antagonized both N 2 O-and chlordiazepoxideinduced increases in the time spent in the light compartment. 81, 88 The antagonism of N 2 O was duplicated by NO scavenger hemoglobin 89 as well as an antisense oligodeoxynucleotide against neuronal NOS. 89 These findings suggest that NO plays a key role in the anxiolytic signaling mechanism downstream from the benzodiazepine/GABA A receptor complex. 88 The key role of NO in anxiolysis was also evidenced by the anxiolyticlike effects of a centrally administered NO donor. 90 The soluble 3Ј,5Ј-cyclic guanosine monophosphate (cGMP)-dependent pathway has been identified by many studies as the main signal transduction pathway of NO. 42 In experiments in the light/dark exploration test, N 2 O anxiolysis was blocked by the guanylyl cyclase inhibitor ODQ (1H- [1, 2, 4] oxadiazolo [4,3-␣] quinoxalin-1-one) and the GMP-dependent protein kinase (PKA)/ cGMP-dependent protein kinase (PKG) inhibitor H8 (N-[2-(methyl-amino)ethyl]-5-isoquinoline sulfonamide HCl) and was potentiated by the cyclic GMP phosphodiesterase inhibitor zaprinast.
91 cGMP is known to act upon several different targets: cGMP-dependent protein kinases (PKG), cGMP-fated cation channels, or cGMPregulated phosphodiesterase. 92 
ANESTHESIA
N 2 O has a well-known role in medical history because it was the first drug used for surgical anesthesia. Despite its limited anesthetic potency, N 2 O is the most widely used general anesthetic agent. With a minimum alveolar concentration of 104% in humans, N 2 O by itself would require high volume percentage and hyperbaric conditions to achieve anesthesia in 50% of subjects. 94 Therefore, because of its low potency, in clinical practice, N 2 O is generally used to reduce the minimum alveolar concentration of a second inhalation agent for anesthesia and increase the rate of induction (ie, the second gas effect 95 ) and to provide or augment the analgesic component of general anesthesia.
General anesthetics like N 2 O have long been hypothesized to act in a nonspecific manner on neuronal membranes, alter membrane fluidity, and/or influence ion channels. But more recently, it has been suggested that general anesthetics might act on one or more superfamilies of ligand-gated ion channels that include GABA A , glycine, nicotinic acetylcholine, 5-hydroxytryptamine 3 , and glutamate receptors. 96, 97 Among the ligand-gated ion channels, the GABA A receptor is considered to be a prime target of volatile and intravenous anesthetics. Several anesthetics are known to potentiate the activity of GABA at inhibitory GABA A receptor. N 2 O itself has been reported to affect various ligand-gated ion channels. [98] [99] [100] N-methyl-D-aspartate (NMDA)-type glutamate receptors have recently emerged as a possible target of inhalation anesthetic drugs. Studies in cultured rat hippocampal neurons revealed that N 2 O inhibited NMDAactivated currents in a dose-dependent manner but had no effect on GABA-activated currents.
101 Consistent with NMDA antagonism, N 2 O is reported to up-regulate binding of NMDA radioligand in the cerebral cortex. 102 N 2 O also inhibited excitotoxic neurodegeneration that is mediated through NMDA receptors. Similar to other NMDA antagonists, the neurotoxic effect of N 2 O is agedependent and is sensitive to attenuation by GABA-erg- This action facilitates ␥-aminobutyric acid (GABA) activation of its binding site, resulting in chloride ion influx. The increased chloride ion concentration in the neuron might cause activation of calmodulin (CaM), which then activates the enzyme nitric oxide synthase (NOS). NOS converts the amino acid L-arginine (L-Arg) to Lcitrulline (L-Cit) and NO, which stimulates the enzyme soluble guanylyl cyclase producing the second messenger cyclic guanosine monophosphate (cyclic GMP). The cyclic GMP, in turn, stimulates a cyclic GMP-dependent protein kinase (PKG) that leads to the anxiolytic drug effect.
ic drugs. 103, 104 It is suggested that a common property of NMDA receptor antagonism may underlie the similar pharmacological profiles of N 2 O and ketamine, an intravenous dissociative anesthetic. The 2 drugs, in fact, produce synergistic neurotoxicity when used together.
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SUMMARY
It is apparent from the above discussion that N 2 O has multiple mechanisms of action that underlie its varied pharmacological properties. Current research indicates that the analgesic effect of N 2 O appears to be initiated by stimulated neuronal release of endogenous opioid peptides, with subsequent activation of opioid receptors and descending GABA and noradrenergic pathways that modulate nociceptive processing at the spinal level. The anxiolytic effect of N 2 O involves activation of the GABA A receptor through the benzodiazepine binding site, although whether N 2 O acts directly or indirectly upon the latter targets remains uncertain. The anxiolytic pathway that is stimulated includes a segment that involves a sequence of 3 key enzymes, NOS, soluble guanylyl cyclase, and PKG. The anesthetic effect of N 2 O appears to be caused by inhibition of NMDA glutamate receptors and removing its excitatory influence in the nervous system.
